TY  - JOUR
AU  - Velayutham, Gurunathan
AU  - Chidambaram, Sathishkumar
AU  - Hariharan, Govindasamy
AU  - Karumalaiyan, Palanisamy
AU  - Periyanayagam, Arockia Doss
T1  - Natural antiviral flavonoids: Striking successful repurposing against COVID-19 through in-silico docking
JO  - Journal of Stress Physiology & Biochemistry
Y1  - 2025/august
VL  - 21
IS  - 3
SP  - 114
EP  - 127
UR  - http://www.jspb.ru/issues/2025/N3/JSPB_2025_3_114-127.pdf

KW  - Antiviral
KW  - ADME
KW  - COVID-19
KW  - Remdesivir
KW  - Volkensiflavone
KW  - Molecular docking

U1  - 1997-0838




N2  - Repurpose of recognized compounds and medications as anti-COVID 2019 (anti-CoVID-19) agents, in anti-SARS-CoV-2 operation, via biological re-assessment of their activities, is a recent and durable development for pandemic COVID-19 novel drugs in 2020. Even so, nearly all of the recorded inhibitors of the various phases of SARS-CoV-2 progression lacks severe forces towards main fateful SARS-CoV-2 enzymes (like the papain protease "PLpro", main protease "Mpro", and RNA-based RNA polymerase "RdRp"). The main objective of this article is to estimate and classify natural antiviral flavonoids as inhibitor medicines like Quercetin, Quercetagetin, Volkensiflavone, Ternatin, Meliternatin, Formononetin, Afromosin, Chrysosplenol B, Chrysosplenol C and Axillarin for COVID-19 main protease and compared with antiviral medication Remdesivir. In-silico docking studies devours natural flavonoid derivative Volkensiflavone was of exceptional inhibition ability (Binding energy-8.9, -9.0 kcal/mol) of 5N5O and 6LU7 enzyme, relative to the other compounds and Remdesivir antiviral medication (Binding energy -7.4 and -7.7 Kcal/mol). The need for the most time is the prompt discovery and commitment of appropriate medication to tackle and convince the global COVID-19 crisis. Besides, timely in vivo experiments takes place to approve inhibition efficacy of anti-SARS-CoV-2 compounds might save people are warranted.
ER  -